이전 사이트 이동

Lycium barbarum and scopoletin are widely used in oriental Eastern medicine and are often consumed as teas. In this study, proinflammatory cytokines expressed in human keratinocytes (HaCaT) were induced by skin diseases caused by 2,4-dinitrochlorobenzene (DNCB) and tumor necrosis factor alpha (TNF-α)/interferon gamma (IFN-γ). The inhibitory activity of L. barbarum EtOH extract (LBE) and scopoletin on proinflammatory cytokines and chemokines was investigated. In the DNCB-induced animal model, oral administration of LBE inhibited skin lesions and proinflammatory cytokines and chemokines and showed inhibitory effects in vitro. Additionally, as a result of examining the efficacy of scopoletin isolated from L. barbarum, scopoletin in HaCaT cells showed inhibitory effects on proinflammatory cytokines and chemokines. It shows promise in the treatment of chronic skin diseases.

Skin hypersensitivity by setting the extraction process to improve the yield and active ingredient content of the marine biological resource, evaluation of the function to reduce the skin immune activity of the extract, deriving indicators and active ingredients, establishing a standard method, and conducting an analysis method validation study Securing base data for development as a functional material to improve response

Ⅰ. Title Prediction of absorption of orally applicable peptide/protein drug candidates fused with macromolecule transduction domain (MTD) using 2D human small intestinal epithelium model Ⅱ. Purpose and necessity of research Goal Development of drug absorption prediction technology for orally administered protein/peptide drug candidates fused with MTD using a two-dimensional functional human intestine epithelial cell model The need for research A two-dimensional functional intestinal epithelial cell model and evaluation test method have been required to solve the company's demanded technology due to the absence of a proper cell model and evaluation test method that can evaluate the absorption rate of orally administered protein/peptide drugs in the small intestine . Ⅲ. Content and scope of R&D ○ Generation and characterization of a two-dimensional human intestinal epithelial cell model for evaluation of the absorption rate of orally administered protein/peptide drugs ○ Gene expression analysis: Gene expression of small intestine specific marker and tight junction marker genes ○ Barrier integrity evaluation: TEER measurement ○ Permeability assay to measure protein/peptide drug absorption and sample harvest for absorption rate analysis Ⅳ. Results Result A. Generation and characterization of a two-dimensional human intestinal epithelial cell model for evaluation of the absorption rate of orally administered protein/peptide drugs ○ Generation the two-dimensional human intestinal epithelial progenitor cell differentiation from human pluripotent stem cells by stepwise directed differentiation methods ○ Establishment of mass-production technology through passaging and freezing/thawingof two-dimensional human intestinal epithelial progenitor cells ○ Optimization of functional intestinal epithelial cell differentiation using air liquid interface (AL)I culture technology B. Gene expression analysis ○ Analyze the expression of small intestine-specific expression markers and tight junction marker genes ○ Analysis of gene expression of specific functional transporters and drug metabolism-related enzymes in a small intestine epithelial model C. Barrier integrity evaluation ○ Optimizing Transwell culture system to perform permeability assay to measure protein/peptide drug absorption a ○ Cell surface structure analysis using SEM for phenotypic observation of intestinal epithelial model and membrane integrity evaluation through TEER measurement D. Absorption evaluation and sample harvest for absorption rate analysis ○ Permeability assay to measure protein/peptide drug absorption ○ Sample harvest for absorption rate analysis (819 case) Ⅴ. Utilization plan of R&D results ○ Evaluation of absorption and metabolism of protein/peptide drug based on human normal intestinal epithelial cell model ○ Increase the efficiency of new protein/peptide drug development; It can be possible to accurately predict the absorption of protein/peptide drug candidates in the preclinical stage, thus increasing the success rate of innovative new protein/peptide drug development ○ Securing competitiveness in peptide/protein pharmaceuticals; By grafting high-functional intestinal epithelial cell model and macromolecular intracellular transport technology, we take technological advantage as a source technology for peptide/protein drug development

Development of basic technology for diagnosis and treatment of rare neurological diseases based on genetic mutation maps, in order to realize precision and adaptive medicine (4P medicine of prevention, prediction, diagnosis, and treatment) for rare neurological diseases

Data-driven target discovery for cancer immunotherapy